NCT01728207View on ClinicalTrials.gov

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Non-hodgkin's LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

IMMU-114

hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.

Trial Locations (5)

19713

Helen F Graham Cancer Center, Newark

31405

Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah

43202

The Ohio State University Comprehensive Cancer Center, Columbus

46526

Indiana University Health Goshen Hospital, Goshen

84112

Huntsman Cancer Institute, Univ. Utah, Salt Lake City

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY